Pharma Bloggers Express Differing Opinions on Avandia Revelation and Departure of Pfizer CFO Alan Levin

NEWTOWN, Pa., May 25, 2007 – Two issues dominated pharmaceutical blogs this week: the news about Avandia and the departure of Pfizer’s CFO, Alan Levin. Christiane Truelove, editor of Med Ad News and R&D Directions, summarizes the bloggers’ thoughts in this week’s edition of the PharmaBlogs: Week in Review e-newsletter.

Cardiologist Dr. Steve Nissen of the Cleveland Clinic recently concluded from an analysis that diabetes patients taking Avandia have a 43 percent greater chance of suffering heart attacks than patients taking other or no diabetes medications. Several bloggers defend Avandia’s developer, GlaxoSmithKline, citing weaknesses in Dr. Nissen’s research, while other bloggers provide the company with suggestions on how to positively deal with the situation.

Alan Levin states his reason for leaving Pfizer is because he wants to “pursue career opportunities outside Pfizer”, but blogger Dr. Peter Rost believes that allegations from a former Pfizer financial executive are the hidden cause.

Pharma professionals who wish to subscribe to PharmaBlogs: Week in Review may visit www.pharmalive.com/enewsletters.


About PharmaBlogs: Week in Review
Designed as a time-effective approach to keeping current on the industry’s blog discussions, PharmaBlogs: Week in Review is the first online newsletter focused on recapping pharmaceutical blogs. The e-newsletter is published by industry information provider Engel Publishing Partners and sent to your e-mail inbox each Friday.

About Engel Publishing Partners
For 25 years, Engel Publishing Partners has been the source that pharmaceutical executives turn to for the information they need to create competitive business strategies. Engel Publishing Partners carries a full product line, offering industry-leading publications Med Ad News and R&D Directions, informative newsletters, and data-rich interactive products. Through these channels, Engel Publishing Partners disseminates original and un-biased content that provides insight into industry trends and events, as well as extensive analysis of companies, products, and pipelines.

Posted: May 2007


View comments

Hide
(web2)